Jennifer M. Pyles

Dr. Jennifer M. Pyles

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
JLJennifer Larson-Casey
Jennifer Larson-Casey
SLShanrun Liu
Shanrun Liu
JPJennifer M. Pyles
Jennifer M. Pyles
SLSuzane Lapi
Suzane Lapi
KSKomal Saleem
Komal Saleem
ACA. Brent Carter
A. Brent Carter
Emerging data indicate an association between environmental heavy metal exposure and lung disease, including lower respiratory tract infections (LRTIs). Here, we show by single-cell RNA sequencing an increase in Pparg gene expression in lung macrophages from mice exposed to cadmium and/or infected with Streptococcus pneumoniae . However, the heavy metal cadmium or infection mediated an inhibitory posttranslational modification of peroxisome proliferator-activated receptor γ (PPARγ) to exacerbate LRTIs. Cadmium and infection increased ERK activation to regulate PPARγ degradation in monocyte-derived macrophages. Mice harboring a conditional deletion of Pparg in monocyte-derived macrophages had more severe S . pneumoniae infection after cadmium exposure, showed greater lung injury, and had increased mortality. Inhibition of ERK activation with BVD-523 protected mice from lung injury after cadmium exposure or infection. Moreover, individuals residing in areas of high air cadmium levels had increased cadmium concentration in their bronchoalveolar lavage (BAL) fluid, increased barrier dysfunction, and showed PPARγ inhibition that was mediated, at least in part, by ERK activation in isolated BAL cells. These observations suggest that impaired activation of PPARγ in monocyte-derived macrophages exacerbates lung injury and the severity of LRTIs.

1 August 2021 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
JPJennifer M. Pyles
Jennifer M. Pyles
AMAdriana V.F. Massicano
Adriana V.F. Massicano
JAJean-Pierre Appiah
Jean-Pierre Appiah
JBJennifer Bartels
Jennifer Bartels
AAAaron Alford
Aaron Alford
SLSuzane Lapi
Suzane Lapi

8 July 2025 in ACS Omega
Verified
Journal Article
Open access
JPJennifer M. Pyles
Jennifer M. Pyles
TITrenton E. Irvin
Trenton E. Irvin
ARAmy Renne
Amy Renne
SHSteffen Happel
Steffen Happel
JNJerry Nolen
Jerry Nolen
SLSuzane Lapi
Suzane Lapi
Terbium-155 (t1/2 = 5.32 days) is one of four medically relevant radioisotopes of terbium. It is of interest to the field as a suitable diagnostic counterpart for therapeutic radiolanthanides, as its decay scheme includes γ-rays that are suitable for single photon emission computed tomography (SPECT) imaging. Additionally, 155Tb has an Auger electron (AE) yield that is viable for AE therapy. There are several direct and indirect production routes that can produce 155Tb. Two possible direct routes include proton irradiation on gadolinium targets via 155Gd­(p,n)155Tb and 156Gd­(p,2n)155Tb. The 155Gd­(p,n)155Tb reaction is accessible at incident proton beam energies of ∼10 MeV, whereas the 156Gd­(p,2n)155Tb nuclear reaction requires ∼18 MeV. This study aims to investigate the production of 155Tb from natGd through the natGd­(p,x) nuclear reaction, wherein both (p,n) and (p,2n) reactions were leveraged, and the purification using a three-column ion chromatography method. Using this system, recoveries of radioterbium of up to 97% were achieved in addition to high recoveries of the Gd target material, illustrating the suitability of this technique for enriched targets.

5 June 2025 in Separation and Purification Technology
Verified
Journal Article
Closed access
JPJennifer M. Pyles
Jennifer M. Pyles
JEJeffrey D Einkauf
Jeffrey D Einkauf
DRDebmalya Ray
Debmalya Ray
LSLuke Sadergaski
Luke Sadergaski
LDLætitia H. Delmau
Lætitia H. Delmau
JBJonathan Burns
Jonathan Burns

11 November 2025 in Dalton Transactions
Verified
Journal Article
Open access
BMB. D. Imansha Madhushan
B. D. Imansha Madhushan
AOAdrianna L. Orsi
Adrianna L. Orsi
JPJennifer M. Pyles
Jennifer M. Pyles
JBJonathan Burns
Jonathan Burns
Loading and retention of Cr 3+ and La 3+ into the alkali metal-substituted alpha-zirconium phosphate.

18 April 2026 in Small Science
Verified
Journal Article
Open access
BMB. D. Imansha Madhushan
B. D. Imansha Madhushan
AOAdrianna L. Orsi
Adrianna L. Orsi
JPJehan S. Perera
Jehan S. Perera
JPJennifer M. Pyles
Jennifer M. Pyles
CLChristine C. Lawrence
Christine C. Lawrence
JBJonathan Burns
Jonathan Burns
The ion exchange behavior of K‐ and Cs‐derivatives of α‐zirconium phosphate, A‐ZrP, with the targeted alpha therapy (TAT) radionuclide 211 At, as At + and AtO + , has been investigated. The K‐ZrP shows strong affinity for both At + and AtO + , ≥99% uptake. The affinity to Cs‐ZrP was less pronounced, 87%–94% uptake, favoring At + . The binding strength was tested against several leaching solutions, including carbonate, phosphate buffered saline (PBS), 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid (HEPES) buffers, and ethylenediaminetetraacetic acid (EDTA) solutions at various concentrations (0.1–10 mM). K‐ZrP retained 211 At in all buffer and EDTA solutions up to 1 mM (<0.5% leaching). The Cs‐ZrP showed no leaching of At + , while AtO + leached (1%–3%) in the carbonate and HEPES buffers, along with all of the EDTA solutions, with complete retention only in the PBS buffer. In all cases, when the EDTA concentration reached 10 mM, 211 At leaching was observed. Once incorporated into the ZrP nanoplatelets, significant shielding of the α‐particles was observed, not only attenuating the intensity of the emission but also reducing the energy of the α‐particles themselves exiting the nanoplatelets. These properties provide the basis for K‐ZrP, and to a lesser extent, Cs‐ZrP to be further considered as potentially promising candidates for a delivery mechanism of 211 At for application in TAT.